We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/1/2018 13:03 | PFE will come back for AGN imv. SAN beginning to look interesting, another 4-5% lower might have a few. | essentialinvestor | |
18/1/2018 13:02 | Support gone? | mbmiah | |
18/1/2018 12:29 | Why is this still falling? Because of revised revenue to 17-18bn? Or some of the big guys like Pfizer not looking to buy? | superman21 | |
18/1/2018 11:06 | Quite apart from issues specific to Shire,the sector is suffering from to accelerating trend in the USA to cut health care costs by punitive action re drug costs.Hilary was bad but Trump might be worse,either way,there seems to be a consensus in the USA which could keep pharmas under a cloud.Shire's cheap but could well stay cheap in such an environment.Long term a buy. | steeplejack | |
18/1/2018 10:45 | Bagged a few at 3421p, surprised to see it this low but buying into weakness at Shire has always worked out well in the past. Does seem entirely sentiment driven and at some point fundamentals will force a restore to a fairer value. Is this big players punishing the board for not pushing ahead with a split in Q1? If it follows a similar pattern as yesterday we can expect a revisit of the 3420p level later today so punter who missed the low this morning will likely get another chance I think. Update - picked up more at 3417p | romeike | |
18/1/2018 10:33 | Bought close to support 3420p, too good too miss at these levels, ex divi in March, put into the ISA | ny boy | |
18/1/2018 09:57 | EI - you may well be correct given the continued fall this morning, though I still believe that the low share prices of certain pharma stocks at the moment represent a bargain opportunity for patient investors. Now looking at two significant declines over two days on no news as part of a general decline since the start of the year with almost every day showing a drop. | romeike | |
18/1/2018 09:53 | 18th jan Liberum hold tp 4000p cut from 4100p | philanderer | |
18/1/2018 09:23 | Rome, I tend to look at a valuation that includes net debt, which is approx 50 Billion. FCF is the metric to focus on imv. If current FCF can be maintained around these levels, Shire look cheap to me, the market may be suggesting some doubt on that. | essentialinvestor | |
17/1/2018 18:31 | Do you think Shire is maybe worth less than £30bn, if not they you are maybe buying at the bottom of a multi year trading range into a share that could quite reasonably increase 50% from its current position. | romeike | |
17/1/2018 16:50 | Have to say was very tempted today but just could not bring myself to buy, that's probably a bullish sign!. | essentialinvestor | |
17/1/2018 12:18 | Juno Therapuetics up 50%, Celgene looking to buy | superman21 | |
17/1/2018 12:04 | superman , tend to agree , hopefully anyway :-) | philanderer | |
17/1/2018 10:16 | Wasn't so sure about it dropping as far as 34.50 so bought a good chunk of shares at 34.92. | romeike | |
17/1/2018 10:13 | Pfizer driving the price lower for buyout 🙂? | superman21 | |
17/1/2018 09:51 | Just made the target prices up from thin air I reckon | mbmiah | |
17/1/2018 09:33 | Can't see anything justifying a valuation of Shire at just £31Bn, pretty ridiculous, I think Shire was what £25-£28B | romeike | |
17/1/2018 09:29 | So who are the brokers giving the 'strong buys' , can't see them ? | philanderer | |
17/1/2018 09:09 | TRY Hargraves, hl dot co dot uk | demo trader | |
17/1/2018 09:08 | Can`t see any 'strong buys' ;-) 15th jan ShoreCap buy - 15th jan Liberum hold tp 4100p 11th jan Deutsche buy tp 5000p 10th jan JP Morgan overweight tp 5000p 9th jan Citigroup buy tp 5500p 2nd jan Piper Jaffray neutral tp $154 20th dec Jefferies buy tp 4900p 29th nov Soc Gen buy tp 8000p 24th nov Goldmans conviction buy tp 6000p 21st nov HSBC hold tp 3800p 6th nov Berenberg buy tp 6000p 1st nov Kepler buy tp 4600p 30th oct Credit Suisse outperform tp 4500p 30th oct Barclays equalweight tp 4000p 27th oct Cantor buy tp $222 27th oct Zacks hold - 27th oct ++++ Q3 results ++++ | philanderer | |
17/1/2018 09:04 | Out of 14 analysts 0 For Sell/strong Sell 3 Neutral 2 Buy 9 Strong buy LOCK THEM UP :-) And release them if bid comes. | demo trader | |
17/1/2018 08:40 | Awful drop to 3450 I'm afraid | mbmiah | |
17/1/2018 08:38 | Oh dear , that quadruple bottom is not going to hold. 3400p anyone ? | philanderer | |
16/1/2018 22:28 | Zak's opinion piece was written before the hot money exited on the 8th after the conference. M&A may happen this year, but possibly not until H2 in my view when things become clearer re restructuring. Maybe but who the hell knows. Sp will likely be in the doldrums again until the next announcement, Feb 14, and to be honest any dramatic moves then are likely to be in the wrong direction. Reading the above, you'd wonder why I'm still a holder :) | ruethewhirl | |
16/1/2018 16:32 | No buyout rumour necessary, as Mir says, it could go back to £45 alone quite easily | romeike |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions